Fast dendritic cells matured with Poly (I:C) may acquire tolerogenic properties

详细信息    查看全文

• 作者：Bojan Pavlović¹ ; Sergej Tomić² ; Jelena Đokić² ; Sa&scaron ; a Vasilijić³ ; Dragana Vučević³ ; Jovanka Lukić⁴ ; Alisa Gruden-Movsesijan⁵ ; Nata&scaron ; a Ilić⁵ ; Milan Marković² ; ⁶ ; Miodrag Čolić² ; ⁶ ; ^{mjcolic@eunet.rs" class="auth_mail" title="E-mail the corresponding author}
• 关键词：cancer immunotherapy ; fast dendritic cells ; Poly (I ; C) ; tolerance ; T-regulatory cells
• 刊名：Cytotherapy
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：17
• 期：12
• 页码：1763-1776
• 全文大小：1707 K

文摘

Because of the labor-intensive and time-consuming conventional protocols for the generation of dendritic cells (DCs) as the most promising tools for anti-cancer therapy that enable the induction of a T-helper (Th)1-mediated anti-tumor immune response, the use of short-term protocols has been proposed. However, data on the applicability of such protocols in cancer immunotherapy are quite limited.

d="absSec_2">Methods

d="abspara0015">We compared the phenotypic and functional capability of fast DCs (fDCs) differentiated for 24 h and then matured for 48 h with Poly (I:C), a strong Th1-promoting agent, with donor-matched conventional DCs (cDCs) differentiated for 5 days and matured likewise.

d="absSec_3">Results

d="abspara0020">Of 12 donors tested, we identified seven whose monocytes failed to develop into immunogenic DCs through the use of fDC protocol, on the basis of incomplete downregulation of CD14, low expression of CD1a and macrophage-like morphology. Such fDCs have significantly lower expression of CD83, CD86, CCR7 and CD40, weaker allo-stimulatory Th1- and Th17-polarizing capacity caused by poor production of interleukin (IL)-12p70 and IL-23 and high production of IL-10, and prominent Th2-polarizing capacity, compared with donor-matched cDCs. Furthermore, such fDCs had tolerogenic properties as judged by higher expression of indolamine dioxigenase-3, IDO-1 and IL-1β and induction of a higher percentage of CD4⁺CD25⁺FoxP3⁺ T cells. These findings correlated with increased transforming growth factor (TGF)-β production by fDC-primed CD3⁺T cells and their stronger anti-proliferative capacity.

d="absSec_4">Conclusions

d="abspara0025">We emphasize that although fDCs could probably be applied as an alternative to cDCs for cancer therapy, the fDC protocol should not be applied to donors whose DCs acquire tolerogenic capabilities.